Holen Sie sich die Stockscreener-App
2.86
4.35%
-0.13
Handel nachbörslich:
2.85
-0.010
-0.35%
Schlusskurs vom Vortag:
$2.99
Offen:
$3
24-Stunden-Volumen:
428.16K
Relative Volume:
2.55
Marktkapitalisierung:
$159.88M
Einnahmen:
$26.03M
Nettoeinkommen (Verlust:
$-17.12M
KGV:
-2.8709
EPS:
-0.9962
Netto-Cashflow:
$-24.53M
1W Leistung:
-1.38%
1M Leistung:
+15.32%
6M Leistung:
+78.75%
1J Leistung:
+353.97%
1-Tages-Spanne:
$2.75
$3.07
1-Wochen-Bereich:
$2.55
$3.07
52-Wochen-Spanne:
$0.54
$3.82
Connect Biopharma Holdings Ltd Stock (CNTB) Company Profile
Firmenname
Connect Biopharma Holdings Ltd
Sektor
Branche
Telefon
858-727-1040
Adresse
3580 CARMEL MOUNTAIN ROAD, SUITE 200, SAN DIEGO
Compare CNTB vs VRTX, REGN, ARGX, ALNY, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CNTB
Connect Biopharma Holdings Ltd
|
2.86 | 167.15M | 26.03M | -17.12M | -24.53M | -0.9962 |
VRTX
Vertex Pharmaceuticals Inc
|
434.30 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
763.04 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
748.25 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
330.34 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
163.81 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Connect Biopharma Holdings Ltd Stock (CNTB) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-01 | Eingeleitet | Lake Street | Buy |
| 2025-10-31 | Eingeleitet | BTIG Research | Buy |
| 2025-06-12 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-03-04 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-04-13 | Eingeleitet | Jefferies | Buy |
| 2021-04-13 | Eingeleitet | Piper Sandler | Overweight |
| 2021-04-13 | Eingeleitet | SVB Leerink | Outperform |
Alle ansehen
Connect Biopharma Holdings Ltd Aktie (CNTB) Neueste Nachrichten
Connect Biopharma Holdings Limited Sponsored ADR (NASDAQ:CNTB) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Director at Connect Biopharma (CNTB) takes shares instead of cash pay - stocktitan.net
[Form 4] Connect Biopharma Holdings Ltd Insider Trading Activity - stocktitan.net
Connect Biopharma (NASDAQ:CNTB) Director James Huang Acquires 1,160,000 Shares - marketbeat.com
CNTB Stock Price, Quote & Chart | CONNECT BIOPHARMA HOLDINGS L (NASDAQ:CNTB) - ChartMill
Entity tied to CNTB director James Huang buys 1.16M shares in open market - stocktitan.net
Connect Biopharma (NASDAQ: CNTB) holder Panacea adds 1.16M shares - stocktitan.net
Connect Biopharma (NASDAQ:CNTB) Posts Quarterly Earnings Results, Beats Estimates By $0.03 EPS - marketbeat.com
ETFs Investing in Connect Biopharma Holdings Ltd. Stocks - TradingView
Connect Biopharma Holdings Ltd reports results for the quarter ended December 31Earnings Summary - TradingView
Connect Biopharma Reports 2025 Full-Year Financial Results and Provides Business Update - The Manila Times
Rademikibart drives Connect Biopharma (NASDAQ: CNTB) asthma and COPD strategy - Stock Titan
[8-K] Connect Biopharma Holdings Ltd Reports Material Event - Stock Titan
New asthma and COPD drug data arrive as Connect funds operations into 2027 - stocktitan.net
Connect Biopharma (NASDAQ:CNTB) Receives "Buy" Rating from BTIG Research - marketbeat.com
BTIG Reiterates Buy Rating on Connect Biopharma Hldgs (CNTB) | C - GuruFocus
BTIG reiterates Buy on Connect Biopharma stock after Phase 1 data - Investing.com Australia
BTIG reiterates Buy on Connect Biopharma stock after Phase 1 data By Investing.com - Investing.com South Africa
Connect Biopharma and Bimergen Energy Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - Green Bay Press-Gazette
Connect Biopharma Announces Positive Phase 1 Results for IV Rademikibart, Showing Rapid Lung Function Improvement in Asthma and COPD Patients - Minichart
Connect Biopharma touts rapid IV rademikibart FEV1 gains; Phase 3 atopic dermatitis data impresses - marketbeat.com
Connect Biopharma reports positive Phase 1 data for asthma drug By Investing.com - Investing.com Australia
Connect Biopharma raises $20.2 million in private placement By Investing.com - Investing.com South Africa
Connect Biopharma stock jumps on positive drug trial results By Investing.com - Investing.com India
Connect Biopharma Announces $20.2 Million Private Placement Financing - Bitget
Connect Biopharma raises $20.2 million in private placement - Investing.com
Connect Biopharma Announces Positive Topline Data from its Phase 1 Study of Intravenous (IV) Rademikibart in Patients with Asthma or COPD - Bitget
Connect Biopharma Raises $20.2 Million in Private Placement of 6.13 Million Shares at $3.25 - TradingView
Connect Biopharma reports positive Phase 1 data for asthma drug - Investing.com
Connect Biopharma (NASDAQ: CNTB) nets $20.2M and reports promising rademikibart results - stocktitan.net
Connect Biopharma raises $20.2M, extends cash runway into 2027 - stocktitan.net
Rademikibart Demonstrates Best-in-Class Potential in Phase 3 Atopic Dermatitis Study - GlobeNewswire
A 2-minute IV shot improved breathing fast in asthma and COPD - stocktitan.net
Time To Revisit Connect Biopharma? - RTTNews
Connect Biopharma (CNTB) Expected to Announce Earnings on Monday - MarketBeat
CNTB SEC FilingsConnect Biopharma Holdings Ltd 10-K, 10-Q, 8-K Forms - Stock Titan
If You Invested $1,000 in Connect Biopharma Holdings Ltd (CNTB) - stocktitan.net
CONNECT BIOPHARMA HOLDINGS L (CNTB) Earnings History & Surprises - ChartMill
Connect Biopharma (CNTB) director linked fund reports 12M-share holding - Stock Titan
Epidermolysis Bullosa Market Set for Significant Upswing During the Forecast Period (2025-2034) Amid Rising Therapeutic Advancements | DelveInsight – Company AnnouncementFT.com - Financial Times
[Form 3] Connect Biopharma Holdings Ltd Initial Statement of Beneficial Ownership - Stock Titan
Connect Biopharma (CNTB) president discloses share and option holdings - Stock Titan
Connect Biopharma (CNTB) CEO details stock option and share holdings - Stock Titan
Connect Biopharma (CNTB) SVP lists Ordinary Shares and option grants - Stock Titan
Connect Biopharma (NASDAQ: CNTB) director reports initial share and option holdings - Stock Titan
Connect Biopharma (CNTB) director lists stock option and share stakes - Stock Titan
Connect Biopharma (NASDAQ: CNTB) director reports initial stock option holdings - Stock Titan
Connect Biopharma Touts “Next-Gen Dupixent” Rademikibart, Near-Term Asthma/COPD Readouts - MarketBeat
Finanzdaten der Connect Biopharma Holdings Ltd-Aktie (CNTB)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.87%
0.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):